NewsRoom Articles - Page 91 of 154 - PsychedelicNewsWire (PNW)

MondayJul 12, 2021 3:00 pm

Harvard Launches First-Ever Psychedelics Policy Center

Earlier this week, the Harvard Law School opened a psychedelics policy center, which it believes will be useful to physicians navigating this growing field as more policies of reform are approved. The Project on Psychedelics Law and Regulation, as the center will be known, has been established to promote equity, innovation and safety in psychedelics therapeutics, commerce and research. A press release by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard acknowledges that local and state psychedelics development involves assessments of the effects of policy as well as the possible impact of private companies that seek…

MondayJul 12, 2021 12:42 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the…

FridayJul 09, 2021 2:00 pm

Psychedelics Reemerge as Treatment for Depression in Canada

Research on psychedelics has shown that the substances possess various benefits, some of which can be used to manage mental health conditions such as anxiety, post-traumatic stress disorder and depression. In addition, in Canada individuals who are nearing the end of their lives have been granted exemptions that allow them to use psilocybin as part of their compassionate treatment. A not-for-profit organization headquartered in British Columbia known as TheraPsil has played a crucial role in obtaining most of these exemptions. In addition to this, the organization has also connected patients to doctors and therapists who oversee the use of these…

ThursdayJul 08, 2021 1:04 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at…

ThursdayJul 08, 2021 1:00 pm

Four Clinical Trials That Could Change Treatment for Mental Health Conditions

In the last decade, a lot of clinical research on psychedelic substances has been conducted, with many scientists focusing on their use in treating psychological and mental ailments. This has also led to a surge in investments into psychedelic research, with many results heralding psychedelics as effective alternative medications for various ailments. Before being classified under Schedule I of the Controlled Substances Act in the United States, psychedelics had been used for both medicinal and recreational purposes by different indigenous tribes and cultures for centuries, only becoming popular in Western medicine in the late 1950s and 1960s. Recent studies on…

WednesdayJul 07, 2021 2:15 pm

UNC Prof Determined to Get the High Out of Psychedelics

The ongoing psychedelic renaissance has brought on a new wave of research on psychedelics, with many studies discovering the various therapeutic benefits that the substances possess. In the last 10 years, privately financed clinical studies have demonstrated the value of psychedelics in treating substance use disorders, anxiety and depression, with MDMA being found to be efficacious in the treatment of PTSD. Earlier in 2019, the Food and Drug Administration gave its approval to the first-ever ketamine-based antidepressant. Studies on psilocybin have also found that the compound is very effective in treating depression. However, Dr. Bryan Roth from the UNC School…

TuesdayJul 06, 2021 2:00 pm

New Study to Look into the Use of Psychedelics for Burnout Among Clinicians

The coronavirus pandemic has affected economies and industries around the world, and while things seem to be getting back on track in some sectors, frontline workers still remain the most affected by COVID-19, which has caused millions to die. Data from a poll conducted by EClinicalMedicine, the Lancet, shows that almost 50% of healthcare workers suffered burnouts, nearly 45% suffered work overload, more than 35% admitted to being depressed or feeling anxiety, and more than 60% feared that they had been exposed to the disease and/or could be transmitting it. The survey, which had more than 20,000 healthcare workers from…

TuesdayJul 06, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution Report incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX). “CYBN continues to demonstrate good progress…

FridayJul 02, 2021 12:00 pm

Study Finds Men Who Use Psychedelics Less Likely to Be Violent to Their Partners

Research conducted by scientists from the University of British Columbia has discovered evidence that men who have used psychedelic substances in the past have decreased chances of being involved with violence against their partners. In the study, which was reported in the “Journal of Psychopharmacology,” the scientists note that their findings do not apply to women. The study’s lead author, Michelle Thiessen, who also happens to be a clinical psychology graduate student from the institution’s Okanagan campus, stated that the researchers’ focus was on the link between violence and psychedelic substances. She explained that while the link between violence and…

FridayJul 02, 2021 10:23 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000